ReviewFrontiers in immunology2026
Regulatory T cells and peripheral immune tolerance: key mechanisms and therapeutic strategies for cardiovascular diseases.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circadian control of immune homeostasis in cardiovascular health and disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) remain the leading global cause of disability and mortality, with chronic immune inflammation as their central pathological mechanism. Regulatory T cells (Tregs) and the peripheral immune tolerance they mediate hold a pivotal position and therapeutic potential in CVDs. This review provides a comprehensive overview of Tregs biology, their dysfunction in major CVDs, current therapeutic strategies targeting Tregs, and future directions for achieving immune homeostasis. By moving beyond the traditional focus on numerical deficiency, we highlight the critical role of functional heterogeneity and cellular dysfunction in CVDs pathogenesis, and discuss the emerging therapeutic concept of moving from delaying disease progression to restoring immune homeostasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.